Experts discuss managing edema, fatigue and long-term tolerability of antibody-drug conjugates in breast and lung cancer
read at onclive ↗Neutral
The piece concludes a series on antibody-drug conjugates, noting that cumulative toxicities can restrict long-term treatment.
Dr. Hope Rugo and Dr. Aaron Lisberg point out that edema and fatigue are frequent side effects seen in patients with breast and lung cancers receiving ADC therapy.
They recommend practical steps such as dose modifications, proactive supportive care and regular monitoring to help sustain tolerability and preserve therapeutic benefit.
source
This writeup was produced by pharmadog from original reporting by onclive.
Original headline: “Cumulative ADC Toxicities and Closing Reflections: Managing Edema, Fatigue, and Optimizing Long-Term Tolerability”
read at onclive ↗
comments(0)
5-min edit window · permanent after that